Pharyngeal Muscle Control Mechanisms of Atomoxetine-plus-oxybutynin in Obstructive Sleep Apnea
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Current therapies available for obstructive sleep apnea (OSA) have varying degrees of
efficacy due to the complex nature of the disorder. A reduction in pharyngeal muscle activity
characterizes OSA, and recent research has shown that combining atomoxetine and oxybutynin
improves OSA severity. Thus this may be a viable treatment option. However, the specific
effects of these agents alone and in combination on pharyngeal muscle activity remain
unknown. The current study will look at the impact of each drug on pharyngeal muscles to gain
insight into the mechanisms of this combination.